$19.87
0.60%
Nasdaq, Jan 02, 10:00 pm CET

Innoviva Stock price

$19.87
-1.11 5.29% 1M
+0.47 2.42% 6M
-0.12 0.60% YTD
+2.47 14.20% 1Y
+6.62 49.96% 3Y
+7.39 59.21% 5Y
+9.55 92.54% 10Y
+1.73 9.53% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.12 0.60%

New AI Insights on Innoviva Insights AI Insights on Innoviva

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$1.5b
Enterprise Value
$1.2b
Net debt
positive
Cash
$533.1m
Shares outstanding
74.8m
Valuation (TTM | estimate)
P/E
13.3 | 9.3
P/S
3.8 | 3.7
EV/Sales
3.1 | 3.0
EV/FCF
6.5
P/B
1.5
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$388.5m | $406.2m
EBITDA
$208.0m | $236.1m
EBIT
$167.9m | $179.0m
Net Income
$127.3m | $160.2m
Free Cash Flow
$187.2m
Growth (TTM | estimate)
Revenue
10.1% | 13.2%
EBITDA
11.1% | 22.5%
EBIT
4.1% | 7.3%
Net Income
97.2% | 584.7%
Free Cash Flow
15.3%
Margin (TTM | estimate)
Gross
81.5%
EBITDA
53.5% | 58.1%
EBIT
43.2%
Net
32.8% | 39.4%
Free Cash Flow
48.2%
Financial Health
Equity Ratio
53.1%
Return on Equity
3.4%
ROCE
12.2%
ROIC
15.7%
Debt/Equity
0.3
More
EPS
$1.5
FCF per Share
$2.5
Short interest
9.0%
Employees
127
Rev per Employee
$2.8m
Show more

Is Innoviva a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Innoviva Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Innoviva forecast:

8x Buy
80%
1x Hold
10%
1x Sell
10%

Analyst Opinions

10 Analysts have issued a Innoviva forecast:

Buy
80%
Hold
10%
Sell
10%

Financial data from Innoviva

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
389 389
10% 10%
100%
- Direct Costs 72 72
69% 69%
19%
317 317
2% 2%
81%
- Selling and Administrative Expenses 113 113
2% 2%
29%
- Research and Development Expense 30 30
141% 141%
8%
208 208
11% 11%
54%
- Depreciation and Amortization 40 40
55% 55%
10%
EBIT (Operating Income) EBIT 168 168
4% 4%
43%
Net Profit 127 127
97% 97%
33%

In millions USD.

Don't miss a Thing! We will send you all news about Innoviva directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Innoviva Stock News

Neutral
Business Wire
23 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that the U.S. Food and Drug Administration (FDA) has approved NUZOLVENCE® (zoliflodacin) for oral suspension, a first-in-class, single-dose oral medication for the treatment of uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years and older weig...
Positive
Reuters
23 days ago
The U.S. Food and Drug Administration has approved Innoviva's oral antibiotic for common sexually transmitted infection, offering patients a pill instead of the injection that is currently the only recommended treatment, the regulator said on Friday.
Neutral
Business Wire
24 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced the publication of positive results from a pivotal Phase 3 trial evaluating its investigational single-dose, oral antibiotic zoliflodacin for the treatment of uncomplicated urogenital gonorrhea in The Lancet. The trial was sponsored and led by the Company's not-...
More Innoviva News

Company Profile

Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Head office United States
CEO Mr. Raifeld
Employees 127
Founded 1996
Website www.inva.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today